Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection

AIM: To evaluate efficacy/safety of hepatitis C virus (HCV) protease inhibitor boceprevir with pegylated interferon (PEG-IFN) alfa and weight-based ribavirin (RBV) in a phase 3 trial. METHODS: A prospective, multicenter, phase 3, open-label, single-arm study of PEG-IFN alfa, weight-based RBV, and bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sherman, Kenneth E, Kang, Minhee, Sterling, Richard, Umbleja, Triin, Marks, Kristen, Kiser, Jennifer J, Alston-Smith, Beverly, Greaves, Wayne, Butt, Adeel A, the ACTG 5294 BIRTH Study Team
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Clinical Trials Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295161/
https://www.ncbi.nlm.nih.gov/pubmed/28217259
http://dx.doi.org/10.4254/wjh.v9.i4.217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295161/
https://www.ncbi.nlm.nih.gov/pubmed/28217259
http://dx.doi.org/10.4254/wjh.v9.i4.217

Ejemplares similares